12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Matrix Pharma preclinical data

MATX presented data showing that the combination of FMdC and cisplatin gave up to 2 times the anti-tumor activity in mouse models of non-small cell lung cancer than...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >